ClinicalTrials.gg
RecruitingNCT06769386Updated Feb 11, 2025

Investigation of Muscle Oxygenation in Patients With Rheumatoid Arthritis

An observational study in Rheumatoid Arthritis, sponsored by Kirsehir Ahi Evran Universitesi. Recruiting at 1 site in Turkey. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-02-11.

Sponsored by Kirsehir Ahi Evran Universitesi · Observational

How we know

From the registry’s dates

  • Primary completion was expected by Jan 2026, 9 months ago, but the record still lists the study as recruiting.
  • Started Jan 2025; still recruiting 1 year 9 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Cross-sectional
Enrollment
68
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 128 studies in Arthritis, Rheumatoid with a site in Turkey — 14 open to participants now, 19 under way, 2 of them phase 3. Arthritis, Rheumatoid · Turkey.

Planned enrollment
37th of 50
68 · median 100
Started
2025
with 17 others
Observational
50 of 128
9 open now
Primary completion
2026-01
later than 11 of 18 live
Registered
96th of 128
by date
Lead sponsor
6 of 128
Kirsehir Ahi Evran Universitesi

Among the 128 studies in Arthritis, Rheumatoid with a site in Turkey, this one is the 37th largest by planned enrollment of the 50 observational ones that give a count, is one of 18 that started in 2025, is one of 50 observational ones, reaches primary completion later than 11 of the 18 other live ones, and was the 96th registered.

Arthritis, Rheumatoid

3,339 studies on the registry are indexed under Arthritis, Rheumatoid; 446 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

14 of the 128 studies in Arthritis, Rheumatoid with a site in Turkey are open now. Recruiting first, the newest first:

8 more — sign in →

All 14 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 293 Arthritis, Rheumatoid studies recruiting now, 151 (52%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 128 studies in Arthritis, Rheumatoid with a site in Turkey, or all of them as a file.
02

Study summary

The aim of this study is to investigate respiratory muscle strength, respiratory muscle endurance, muscle oxygenation, upper extremity and lower extremity exercise capacity in rheumatoid arthritis patients compared with healthy individuals.

Read the detailed description

Rheumatoid arthritis (RA) is a chronic progressive autoimmune disease of unknown etiology with symmetric erosive synovitis and multisystem involvement. The disease causes significant long-term morbidity, reduced functional capacity, and increased mortality rates. Patients with rheumatoid arthritis avoid physical activity due to pain and fatigue. Despite the advances in pharmacological treatments in recent years, functional losses due to rheumatic diseases the resulting deterioration in quality of life, and loss of work continue. Physical inactivity is known to have detrimental effects on the cardiovascular and pulmonary systems by reducing muscle strength and aerobic capacity. The physiological reasons underlying skeletal muscle oxygenation that may cause muscle dysfunction in rheumatoid arthritis have not been investigated. In these patients, decreased arterial oxygen may reduce exercise capacity and cause muscle deoxygenation.

In rheumatoid arthritis patients, decreases in respiratory muscle strength, lung volumes, oxygen consumption, and six minute walk test distance cause cardiopulmonary deconditioning. Decreased exercise capacity increases the risk of cardiovascular disease and causes mortality in patients with RA.

This study aimed to, the effects of respiratory muscle strength, respiratory muscle endurance, upper and lower extremity muscle oxygenation, and upper and lower extremity exercise capacity in patients with stable disease activity.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • exercise capacity
  • muscle oxygenation
  • rheumatoid arthritis
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Non-probability sample

Study population

Rheumatoid arthritis patients (diagnosed according to American College of Rheumatology/European Alliance of Associations for Rheumatology ACR/EULAR 2022 diagnostic criteria) aged between 18-65 years, with a Disease Activity Score (DAS)-28 score below 2.6 in disease remission and followed up at the Rheumatology Polyclinic of the Department of Physical Medicine and Rehabilitation at Kirsehir Ahi Evran University will be included in the study.

As a control group, healthy individuals between the ages of 18-65, who are similar to the patients in terms of age and gender, without any disease, will be included in the study.

Eligibility criteria

Rheumatoid Arthritis Group

Inclusion Criteria:

  • Patients diagnosed with rheumatoid arthritis,
  • The ages of 18-65 years,
  • Volunteer to participate in the study will be included in the study.

Exclusion Criteria:

  • Serious cardiopulmonary, neurological, neuromuscular, orthopedic and other systemic diseases or other diseases affecting physical functions,
  • Participated in a planned exercise program in the last three months,
  • Cognitive impairment that will cause difficulty in understanding and following exercise test instructions,
  • to exercise testing or exercise training according to the American Sports Medicine Association will not be included in the study.

Control Group

Inclusion Criteria:

  • The ages of 18-65 years,
  • Volunteer to participate in the study will be included in the study.

Exclusion Criteria:

  • Diagnosed chronic or systemic disease,
  • Regular exercise (physical activity) 3 days a week, 150 minutes/week of moderate intensity
  • Smoking 10 packs x years or more,
  • Pneumonia or any acute infection,
  • Healthy individuals with any psychiatric disorder will not be included in the study.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Case-control
Time perspective
Cross-sectional
Enrollment
68 participants (estimated)
Patient registry
No

Groups and cohorts

  • Rheumatoid Arthritis Group

    Rheumatoid arthritis patients who are followed up in the Rheumatology Outpatient Clinic of the Department of Physical Medicine and Rehabilitation (diagnosed according to American College of Rheumatology/European Alliance of Associations for Rheumatology ACR/EULAR 2022 diagnostic criteria), aged between 18-65 years, and have a Disease Activity Score (DAS) -28 score below 2.6 in disease remission will be included.

  • Control Group

    As a control group, healthy individuals between the ages of 18-65, who are similar to the patients in terms of age and gender, without any disease, will be included in the study. Healthy individuals in the control group will be selected from volunteer colleagues, school friends, family and residential areas of the researchers to participate in the study.

06

What researchers measure

Primary outcomes

  1. Evaluation of respiratory muscle strength

    An electronic mouth pressure measuring device that complies with American Thoracic Society and European Respiratory Society criteria will be used to assess respiratory muscle strength.

    Time frame: First day

  2. Evaluation of respiratory muscle endurance

    The incremental threshold workload test will be used to assess respiratory muscle endurance.The PowerBreathe Wellness® (HaB International Ltd. Southam, United Kingdom) inspiratory muscle training device will be used in the incremental threshold load test.

    Time frame: First day

  3. Evaluation of Deltoid and Quadriceps Femoris Muscle Oxygenation

    Muscle oxygen level of quadriceps femoris and deltoid muscles will be measured using Moxy® monitor (Moxy, Fortiori Design LLC, Minnesota, USA) before, during and after the six-minute walk test and six-minute peg-board and ring test.

    Time frame: First and second day

  4. Evaluation of Deltoid and Quadriceps Femoris Muscle Total Hemoglobin Level

    Total hemoglobin level of quadriceps femoris and deltoid muscles will be measured using Moxy® monitor (Moxy, Fortiori Design LLC, Minnesota, USA) before, during and after the six-minute walk test and six-minute peg-board and ring test.

    Time frame: First and second day

Secondary outcomes

  1. Evaluation of submaximal exercise capacity

    The six-minute walk test will be performed according to American Thoracic Society criteria to evaluate functional exercise capacity.

    Time frame: First day and second day

  2. Evaluation of upper extremity capacity

    The six-minute peg board and ring test will be used to assess upper extremity exercise capacity.

    Time frame: First day and second day

07

Study locations

1 of 1 sites recruiting
  • Kırşehir Ahi Evran University, Physical Therapy and Rehabilitation Center, Cardiopulmonary Unit
    Kırşehir, Merkez 40100, Turkey
    Recruiting
08

References and documents

Publications

  • Wickerson L, Mathur S, Brooks D, Bonetti LV, Singer LG, Granton J, Reid WD. Skeletal muscle oxygenation and regional blood volume during incremental limb loading in interstitial lung disease. ERJ Open Res. 2020 Jan 27;6(1):00083-2019. doi: 10.1183/23120541.00083-2019. eCollection 2020 Jan. PubMed 32010722 ↗
  • Cimen B, Deviren SD, Yorgancloglu ZR. Pulmonary function tests, aerobic capacity, respiratory muscle strength and endurance of patients with rheumatoid arthritis. Clin Rheumatol. 2001;20(3):168-73. doi: 10.1007/s100670170058. PubMed 11434466 ↗

Individual participant data

Plan to share: No — All data will be stored in a locked cabinet.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jan 2025 (actual). Primary completion is estimated for Jan 2026, 12 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 7, 2025
First posted
Jan 10, 2025
StartActual
Jan 25, 2025
Primary completionEst.
Jan 25, 2026
CompletionEst.
Jan 25, 2027
Last update
Feb 11, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 11, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06769386
Responsible party
Başak KAVALCI KOL (Principal Investigator, Kirsehir Ahi Evran Universitesi) — Principal investigator
First posted
Jan 10, 2025
Start date
Jan 25, 2025
Primary completion
Jan 25, 2026 (estimated)
Completion
Jan 25, 2027 (estimated)
Last update
Feb 11, 2025

Study contacts

Başak KAVALCI KOL, PhD
Contact
basak.kavalci@ahievran.edu.tr
+903862802317
Başak KAVALCI KOL, PhD
principal investigator · Kirsehir Ahi Evran Universitesi
Merve FIRAT, PhD
study chair · Kirsehir Ahi Evran Universitesi
Figen TUNCAY, Prof. Dr.
study chair · Kirsehir Ahi Evran Universitesi

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion